Drugs / βAS3-FB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02247843 | Dec 2014 → Sep 2025 | sickle cell disease | Donald B. Kohn, M.D. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | βAS3-FB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02247843 ↗ |
| Action | Restore | “autologous HSCT using a patient's own peripheral blood stem cells that have been corrected by transfer of a modified human beta-globin gene” NCT02247843 ↗ |
| Modality | Cell therapy | “autologous peripheral blood CD34+ cells transduced ex vivo by the Lenti/G-βAS3-FB lentiviral vector” NCT02247843 ↗ |